Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 4
1995 1
1996 1
1997 2
1998 3
1999 7
2000 3
2001 8
2002 11
2003 12
2004 7
2005 9
2006 12
2007 8
2008 5
2009 8
2010 3
2011 2
2012 3
2013 4
2014 3
2015 8
2016 2
2017 4
2018 11
2019 10
2020 6
2021 15
2022 21
2023 19
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. Among authors: demirkan f. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. Moreno C, et al. Among authors: demirkan f. Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012. Haematologica. 2022. PMID: 35021599 Free PMC article. Clinical Trial.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Burger JA, et al. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6. N Engl J Med. 2015. PMID: 26639149 Free PMC article. Clinical Trial.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Moreno C, et al. Among authors: demirkan f. Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522969 Clinical Trial.
Response to Kottner, Commentary on Sayar S, Turgut S, Doğan H, Ekici A, Yurtsever S, Demirkan F, Doruk N & Taşdelen B (2009) Incidence of pressure ulcers in intensive care unit patients at risk according to the Waterlow Scale and factors influencing the development of pressure ulcers. Journal of Clinical Nursing 18, 765–774.
Yurtsever S, Sayar S, Demirkan F, Taşdelen B. Yurtsever S, et al. Among authors: demirkan f. J Clin Nurs. 2010 Dec;19(23-24):3591-2. doi: 10.1111/j.1365-2702.2009.02818.x. J Clin Nurs. 2010. PMID: 21132863 No abstract available.
Triplicated thumb.
Atabay K, Latifoglu O, Demirkan F, Yavuzer R. Atabay K, et al. Among authors: demirkan f. Plast Reconstr Surg. 1997 Aug;100(2):418-21. doi: 10.1097/00006534-199708000-00023. Plast Reconstr Surg. 1997. PMID: 9252610
Application of apheresis science in Emergency Medicine.
Demirkan F, Tekgündüz E. Demirkan F, et al. Transfus Apher Sci. 2018 Feb;57(1):1. doi: 10.1016/j.transci.2018.02.015. Epub 2018 Feb 21. Transfus Apher Sci. 2018. PMID: 29486924 No abstract available.
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey.
Lamure S, Salmanton-García J, Robin-Marieton E, Jaksic O, Kohn M, Marchesi F, Marchetti M, El-Ashwah S, Demirkan F, Valković T, Fernández N, Tisi MC, Stojanoski Z, Seval GC, Ilhan O, Prezioso L, Merelli M, López-García A, Ledoux MP, Kulasekararaj A, González-López TJ, Gomes da Silva M, Emarah Z, Duarte RF, Cattaneo C, Blennow O, Bilgin YM, Bergantim R, Batinić J, Cordoba R, Essame J, Nordlander A, Nunes Rodrigues R, Sacchi MV, Zompi S, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Duléry R, Cornely OA, Besson C, Pagano L. Lamure S, et al. Among authors: demirkan f. Blood Adv. 2022 Jul 12;6(13):3870-3874. doi: 10.1182/bloodadvances.2022007357. Blood Adv. 2022. PMID: 35500220 Free PMC article. No abstract available.
201 results